Phase 1 N=13 The Maraviroc Central Nervous System (CNS) Study
HIV Infections
Primary: CSF (Cerebrospinal Fluid) : Plasma Ratio of Maraviroc 1H Magnetic Resonance Spectroscopy (1H-MRS) — 1.01 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Cancer Anorexia and the Central Nervous System
Cancer Cachexia
Primary: ACTIVATION/NON ACTIVATION OF SPECIFIC BRAIN AREAS, EVALUATED BY FUNCTIONAL MAGNETIC RESONANCE — 585.57; 667.92; 511.22 BOLD
Phase 2 N=10 Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
Pharmacokinetics
Primary: Unbound Ceftolozane Exposure in the Plasma — 322.6 mg*h/L
Phase 2 N=336 Indocyanine Green for Central Nervous System Tumors
Suspected Central Nervous System Tumors
Primary: Sensitivity (SBR) — 5.49 ratio
Phase 4 N=20 Temperature Control in Central Fever in the Neuro-ICU
Fever · Brain Hemorrhage
Primary: Core Temperature as Measured With an Approved Device (Urinary Catheter) in Place for Usual Clinical Care — 100.8; 100.3; 99.9; 99.5 degrees F
Phase 3 N=256 Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
CNS Lesion · Blood Brain Barrier Defect
Primary: Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI — 3.90; 2.08; 3.64; 1.74 mean of a score (on a scale) per patient — p=<.0001
N/A N=22 Combined Brain and Peripheral Nerve Stimulation for Stroke
Stroke
Primary: Active Range of Motion of Wrist Extension in the Paretic Side — 37.8; 38; 37.2; 38 degrees
N/A N=105 NEPAL (Neuromodulatory Examination of Pain and Mobility Across the Lifespan)
Musculoskeletal Pain · Pain, Chronic
Primary: Short Physical Performance Battery (SPPB) — 10.95; 10.82; 11.75 score on a scale — p=0.0561
N/A N=38 An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
Central Nervous System Neoplasm · Glioma · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Contrast-to-noise Ratio (CNR) — 60.6; 58.4 contrast-to-noise ratio
N/A N=8 Peripheral Sensory Input in Central Post Stroke Pain (CPSP)
Central Post Stroke Pain
Primary: Reduction in Spontaneous Pain Intensity After a Peripheral Nerve Block. — 6.5; 0.0 units on a scale
Phase 3 N=59 Clinical Trial of CNS-targeted HAART (CIT2)
HIV Infections
Primary: Neuropsychological Performance Change — -0.27; -0.17 units on a scale
N/A N=158 Central Nervous System Amplification in Lumbar Failed Back Surgery Syndrome
Chronic Pain
Primary: Clinical Pain Severity - 50% Reduction Responders vs Nonresponders — -83; 0 percentage of change
N/A N=92 Neuroproprioceptive "Facilitation, Inhibition" and Brain Plasticity
Multiple Sclerosis
Primary: White Matter Integrity — 0.5023; 0.5168; 0.4747 score on a scale
Phase 3 N=343 Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
Central Nervous System Diseases
Primary: Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic…
Phase 3 N=356 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 28.5; 25.3 months — p=0.2853
Phase 2 N=280 P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
CNS Lesion · Blood Brain Barrier Defect
Primary: Contrast to Noise Ratio (CNR) Difference — -10.59; 2.18; 8.66; 14.45 Ratio — p=0.1858
Phase 1 N=24 A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)
Healthy Volunteers
Primary: Change From Baseline in Peak-to-Peak Amplitude of Motor-evoked Potential (MEP) Obtained With Single-pulse Transcranial Magnetic Stimulation (TMS) for TAK-653 at 2.5…
Phase 2 N=219 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
N/A N=76 Neural Basis of Sensory and Motor Learning: Functional Connections
Basic Science
Primary: Resting-state PMv-M1 Functional Connectivity (Fisher Z-transformed Correlation) — 0.64 unitless (Fisher z-score)
Phase 2 N=40 High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
B-cell Lymphomas
Primary: Event-free Survival — 16 Participants
N/A N=19 CSF Pharmacokinetics of Ondansetron
Pain
Primary: CSF to Plasma Concentration Ratio — 0.15 Ratio
Phase 2 N=21 Driving Neuroplasticity With Nerve Stimulation and Modified CIT
Stroke · Cerebrovascular Accident
Primary: Change in Wolf Motor Function Test (WMFT), Timed Portion — -0.36; -0.18; -0.37; -0.15 log(seconds)
Phase 3 N=46 Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates
Herpes Simplex
Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment (Motor Scores). — 10; 5; 0; 1 participants
Phase 2 N=91 Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Chemotherapeutic Agent Toxicity · Cognitive/Functional Effects · Lymphoma
Primary: Progression-free Survival — 2.1; NA years — p=0.015